Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection.

Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection.
复制标题

DOI:
10.3390/pharmaceutics14071352
复制
发表时间:
2022-06-26
期刊:
影响因子:
5.4
通讯作者:
Ahlenstiel, Chantelle L.
Ahlenstiel, Chantelle L.
中科院分区:
医学2区
文献类型:
--
作者:
Agbosu, Esinam E.;Ledger, Scott;Kelleher, Anthony D.;Wen, Jing;Ahlenstiel, Chantelle L.

文献摘要

参考文献

相似文献

自1983年发现艾滋病毒以来,我们对艾滋病毒感染的认识有了很大的进步。各种治疗办法提高了艾滋病毒/艾滋病患者的生活质量,使其从致命疾病转变为可控制的慢性感染。尽管取得了所有这些进展,但治愈方法仍然难以捉摸。实现HIV治愈的一个主要障碍是潜伏病毒库的存在,潜伏病毒库在感染早期建立,并持续宿主的一生,即使在延长的抗病毒治疗期间。目前正在探索不同的治疗策略,以消除或抑制这种水库。几项研究表明,通过预防感染和抑制潜伏宿主中病毒的再活化,可以实现功能性治愈。在这里,我们简要描述了主要的HIV治疗策略,重点是使用RNA治疗,包括小干扰RNA(siRNA)以使HIV永久保持在超潜伏状态,以及CRISPR gRNA以切除潜伏水库。将RNA治疗进展到临床的挑战是实现有效递送到宿主细胞中。这篇综述涵盖了最近的纳米技术策略,使用脂质体,N-乙酰半乳糖胺共轭,无机纳米粒子和聚合物为基础的纳米胶囊的siRNA交付。我们进一步讨论了这些艾滋病毒治疗战略的机遇和挑战。
Our understanding of HIV infection has greatly advanced since the discovery of the virus in 1983. Treatment options have improved the quality of life of people living with HIV/AIDS, turning it from a fatal disease into a chronic, manageable infection. Despite all this progress, a cure remains elusive. A major barrier to attaining an HIV cure is the presence of the latent viral reservoir, which is established early in infection and persists for the lifetime of the host, even during prolonged anti-viral therapy. Different cure strategies are currently being explored to eliminate or suppress this reservoir. Several studies have shown that a functional cure may be achieved by preventing infection and also inhibiting reactivation of the virus from the latent reservoir. Here, we briefly describe the main HIV cure strategies, focussing on the use of RNA therapeutics, including small interfering RNA (siRNA) to maintain HIV permanently in a state of super latency, and CRISPR gRNA to excise the latent reservoir. A challenge with progressing RNA therapeutics to the clinic is achieving effective delivery into the host cell. This review covers recent nanotechnological strategies for siRNA delivery using liposomes, N-acetylgalactosamine conjugation, inorganic nanoparticles and polymer-based nanocapsules. We further discuss the opportunities and challenges of those strategies for HIV treatment.
DOI: 10.1038/mtna.2015.31
发表时间: 2015-10-27
期刊: Molecular therapy. Nucleic acids
影响因子: --
作者:
Ahlenstiel C;Mendez C;Lim ST;Marks K;Turville S;Cooper DA;Kelleher AD;Suzuki K
通讯作者: Suzuki K
DOI: 10.1038/s41565-021-00928-x
发表时间: 2021-09
影响因子: 38.3
作者:
Dammes N;Goldsmith M;Ramishetti S;Dearling JLJ;Veiga N;Packard AB;Peer D
通讯作者: Peer D
DOI: 10.1016/j.apsb.2020.10.005
发表时间: 2020-11
期刊: Acta pharmaceutica Sinica. B
影响因子: --
作者:
Charbe NB;Amnerkar ND;Ramesh B;Tambuwala MM;Bakshi HA;Aljabali AAA;Khadse SC;Satheeshkumar R;Satija S;Metha M;Chellappan DK;Shrivastava G;Gupta G;Negi P;Dua K;Zacconi FC
通讯作者: Zacconi FC
玉米中高频靶向诱变的农杆菌销售的CRISPR/CAS9系统。
DOI: 10.1111/pbi.12611
发表时间: 2017-02
影响因子: 13.8
作者:
Char SN;Neelakandan AK;Nahampun H;Frame B;Main M;Spalding MH;Becraft PW;Meyers BC;Walbot V;Wang K;Yang B
通讯作者: Yang B
DOI: 10.3390/pathogens10111517
发表时间: 2021-11-20
期刊: Pathogens (Basel, Switzerland)
影响因子: --
作者:
Acchioni C;Palermo E;Sandini S;Acchioni M;Hiscott J;Sgarbanti M
通讯作者: Sgarbanti M